RKV — Rakovina Therapeutics Balance Sheet
0.000.00%
- CA$6.34m
- CA$7.48m
Annual balance sheet for Rakovina Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.474 | 0.808 | 2.81 | 0.897 | 0.436 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.001 | 0.006 | 0.074 | 0.015 | 0.02 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.495 | 0.814 | 3.07 | 1.07 | 0.633 |
Net Intangible Assets | |||||
Total Assets | 0.495 | 0.814 | 8.66 | 6.12 | 5.15 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.02 | 0.042 | 0.114 | 0.107 | 0.155 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.02 | 0.042 | 0.114 | 0.107 | 1.49 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.475 | 0.772 | 8.54 | 6.01 | 3.66 |
Total Liabilities & Shareholders' Equity | 0.495 | 0.814 | 8.66 | 6.12 | 5.15 |
Total Common Shares Outstanding |